^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

First-in-human, multicenter phase Ⅰ study of TGRX-326 in patients with advanced ALK-positive non-small cell lung cancer.

Published date:
05/25/2023
Excerpt:
TGRX-326 demonstrated antitumor activity against multiple ALK mutations including G1202R.
DOI:
10.1200/JCO.2023.41.16_suppl.9113
Trial ID: